open access

Vol 6, No 1 (2008)
Research paper
Published online: 2008-05-12
Get Citation

Declaring sexual dysfunction symptoms during the psychotherapy of anxiety disorders

Aleksandra Jodko, Jacek Głowacz, Andrzej Kokoszka
Seksuologia Polska 2008;6(1):26-32.

open access

Vol 6, No 1 (2008)
Prace oryginalne (nadesłane)
Published online: 2008-05-12

Abstract


Background. Despite numerous data concerning prevalence of sexual dysfunctions, their frequency in different mental disorders has no been reliably evaluated. There are no reports on the number of patients experiencing dysfunctions in anxiety disorders who decide to bring the sexuological problem up during psychotherapy. The aim of the study was to probe: how frequent the sexual dysfunctions are in the progress of anxiety disorders and what influences the decision to bring them up during psychotherapy.
Material and methods. The study was conducted on a group of 104 patients from daily units undergoing psychotherapy for anxiety disorders. The used tool was created for the purpose of the study and was named - Sexual Problems Questionnaire; it enabled the diagnosis of subjective feeling of experiencing sexual dysfunctions, symptoms’ importance, their origin and information concerning dealing with them during group and individual psychotherapy.
Results. 99% of the patients declared having at least one sexual dysfunction, three or more were declared by 49%, two by 21,2%, one by 3,8%, no dysfunctions was declared by just one patient. It turned out that 80% of the study participants do not report sexual symptoms during group therapy, almost 80% of women and over 60% of men do not do it during individual consultations.
Conclusions. A practical indication from the study is that there is a need for clinicians to address the issue of sexual functioning in the progress of anxiety oriented psychotherapy.

Abstract


Background. Despite numerous data concerning prevalence of sexual dysfunctions, their frequency in different mental disorders has no been reliably evaluated. There are no reports on the number of patients experiencing dysfunctions in anxiety disorders who decide to bring the sexuological problem up during psychotherapy. The aim of the study was to probe: how frequent the sexual dysfunctions are in the progress of anxiety disorders and what influences the decision to bring them up during psychotherapy.
Material and methods. The study was conducted on a group of 104 patients from daily units undergoing psychotherapy for anxiety disorders. The used tool was created for the purpose of the study and was named - Sexual Problems Questionnaire; it enabled the diagnosis of subjective feeling of experiencing sexual dysfunctions, symptoms’ importance, their origin and information concerning dealing with them during group and individual psychotherapy.
Results. 99% of the patients declared having at least one sexual dysfunction, three or more were declared by 49%, two by 21,2%, one by 3,8%, no dysfunctions was declared by just one patient. It turned out that 80% of the study participants do not report sexual symptoms during group therapy, almost 80% of women and over 60% of men do not do it during individual consultations.
Conclusions. A practical indication from the study is that there is a need for clinicians to address the issue of sexual functioning in the progress of anxiety oriented psychotherapy.
Get Citation

Keywords

sexual dysfunctions; anxiety disorders; psychotherapy superstition

About this article
Title

Declaring sexual dysfunction symptoms during the psychotherapy of anxiety disorders

Journal

Seksuologia Polska (Polish Sexology)

Issue

Vol 6, No 1 (2008)

Article type

Research paper

Pages

26-32

Published online

2008-05-12

Page views

1410

Article views/downloads

2983

Bibliographic record

Seksuologia Polska 2008;6(1):26-32.

Keywords

sexual dysfunctions
anxiety disorders
psychotherapy superstition

Authors

Aleksandra Jodko
Jacek Głowacz
Andrzej Kokoszka

References (85)
  1. Male C, Lensing A, Palumbo J, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute ve-nous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020; 7(1): e18–e27.
  2. Brandão L, Albisetti M, Halton J, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020; 135(7): 491–504.
  3. Branstetter JW, Kiskaddon AL, King MA, et al. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Thromboprophylaxis: A Systematic Review of the Literature. Semin Thromb Hemost. 2021 [Epub ahead of print].
  4. https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf.
  5. https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf.
  6. Cortelazzo S, Marchetti M, Orlando E, et al. Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway. Am J Hematol. 1998; 57(4): 277–282, doi: 10.1002/(sici)1096-8652(199804)57:4<277::aid-ajh2>3.0.co;2-r.
  7. Witmer C, Raffini L. Treatment of venous thromboembolism in pediatric patients. Blood. 2020; 135(5): 335–343.
  8. Bosch A, Albisetti M. Management of Venous Thromboembolism in Chil-dren: Current Recommendations and Therapeutic Options. Ther Clin Risk Manag. 2020; 16(673): 679.
  9. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl): e737S–e801S.
  10. Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018; 2(22): 3292–3316.
  11. Smitherman AB, Alexander T, Connelly M, et al. The incidence of catheter-associated venous thrombosis in noncritically ill children. Hosp Pediatr. 2015; 5(2): 59–66.
  12. Kanin M, Young G. Incidence of thrombosis in children with tunneled central venous access devices versus peripherally inserted central catheters (PICCs). Thromb Res. 2013; 132(5): 527–530.
  13. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14): 987–994.
  14. Connor P, Sánchez van Kammen M, Lensing AWA, et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020; 4(24): 6250–6258.
  15. Carrier M, Wang TF. Direct oral anticoagulants and cancer-associated VTE: good for all, or just some? Blood. 2020; 136(6): 669–673.
  16. Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Hematology Am Soc Hematol Educ Program. 2018; 2018(1): 339–347.
  17. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007; 5(4): 692–699.
  18. Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood. 2005; 106(13): 4027–4033.
  19. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100(10): 3484–3488.
  20. Wojtukiewicz MZ, Sierko E, Tomkowski W. Guidelines for the prevention and treatment of venous thromboembolism in patients with cancers treated conservatively. Oncol Clin Pract. 2016; 12: 67–91.
  21. Kearon C. A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism. J Thromb Haemost. 2012; 10(4): 507–511.
  22. Streiff MB, Agnelli G, Connors JM, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016; 41(1): 32–67.
  23. Lee AYY, Levine MN, Baker RI, et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146–153.
  24. Deitcher SR, Kessler CM, Merli G, et al. ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12(4): 389–396.
  25. Lee AYY, Kamphuisen PW, Meyer G, et al. CATCH Investigators. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015; 314(7): 677–686.
  26. Agnelli G, Verso M, Ageno W, et al. MASTER investigators. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res. 2008; 121(5): 605–610.
  27. Hull RD, Pineo GF, Brant RF, et al. LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006; 119(12): 1062–1072.
  28. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162(15): 1729–1735.
  29. Romera A, Cairols MA, Vila-Coll R, et al. A Randomised Open-Label Trial Comparing Long-term Sub-Cutaneous Low-Molecular-weight Heparin Compared with Oral-Anticoagulant Therapy in the Treatment of Deep Venous Thrombosis. Journal of Vascular Surgery. 2009; 49(3): 815.
  30. Laporte S, Bertoletti L, Romera A, et al. Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients. Thromb Res. 2012; 130(6): 853–858.
  31. Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015; 13(6): 1028–1035.
  32. Krasiński Z, Krasińska B. Commentary on the DALTECAN study. Pol Arch Med Wewn. 2016; 126(3): 204–206.
  33. Pini M, Aiello S, Manotti C, et al. Low Molecular Weight Heparin versus Warfarin in the Prevention of Recurrences after Deep Vein Thrombosis. Thrombosis and Haemostasis. 2018; 72(02): 191–197.
  34. López-Beret P, Orgaz A, Fontcuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001; 33(1): 77–90.
  35. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins, a metaanalysis. Arch Intern Med 1995; 155: 601–607.
  36. Siragusa S, Cosmi B, Piovella F, et al. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996; 100(3): 269–277.
  37. Hettiarachchi R, Prins M, Lensing A, Buller HR. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med 1998; 4: 220–225.
  38. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999; 130(10): 800–809.
  39. Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med. 2000; 160(2): 181–188.
  40. Rocha E, Martínez-González MA, Montes R, et al. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica. 2000; 85(9): 935–942.
  41. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2004; 140(3): 175–183.
  42. Büller HR, Davidson BL, Decousus H, et al. Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004; 140(11): 867–873.
  43. Hakoum MB, Kahale LA, Tsolakian IG, et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018; 1: CD006649.
  44. Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014; 134(6): 1214–1219.
  45. Raskob GE, van Es N, Verhamme P. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7): 615–624.
  46. Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017–2023.
  47. McBane RD, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial. Thromb Haemost. 2017; 117(10): 1952–1961.
  48. Agnelli G, Becattini C, Bauersachs R, et al. Caravaggio Study Investigators. Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thromb Haemost. 2018; 118(9): 1668–1678.
  49. Bellesoeur A, Thomas-Schoemann A, Allard M, et al: Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. Crit Rev Oncol Hematol 2018; 129: 102-112.
  50. Momin W, Goble J, Thotakura S, et al. 5742Increased bleeding events in patients co-administered rivaroxaban and either cyp3A4 or p-gp inhibitors. European Heart Journal. 2017; 38(suppl_1).
  51. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28): 3240–3261.
  52. Mantha S, Laube E, Miao Y, et al. Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis. 2017; 43(2): 166–171.
  53. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. The Lancet. 2012; 379(9810): 31–38.
  54. Kim HS, Preece SR, Black JH, et al. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg. 2008; 47(2): 388–394.
  55. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014; 311(23): 2414–2421.
  56. Mismetti P, Laporte S, Pellerin O. Effect of a Retrievable Inferior Vena Cava Filter Plus Anticoagulation vs Anticoagulation Alone on Risk of Recurrent Pulmonary Embolism: A Randomized Clinical Trial. Journal of Vascular Surgery. 2016; 63(1): 280.
  57. Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014(7): CD006650.
  58. Louzada ML, Majeed H, Wells PS. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res. 2009; 123(6): 837–844.
  59. Ferretti G, Bria E, Giannarelli D, et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest. 2006; 130(6): 1808–1816.
  60. Brunetti ND, Gesuete E, De Gennaro L, et al. Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: A meta-analysis study. Int J Cardiol. 2017; 230: 214–221.
  61. Posch F, Königsbrügge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015; 136(3): 582–589.
  62. Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, et al. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014; 134(4): 774–782.
  63. Kahale LA, Hakoum MB, Tsolakian IG. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. Cochrane Database Syst Rev. 2018; 6: CD006650.
  64. Larsen TB, Nielsen PB, Skjøth F, et al. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One. 2014; 9(12): e114445.
  65. Prins MH, Lensing AWA, Brighton TA, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014; 1(1): e37–e46.
  66. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014; 124(12): 1968–1975.
  67. Vedovati MC, Germini F, Agnelli G, et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest. 2015; 147(2): 475–483.
  68. Napolitano M, Saccullo G, Malato A, et al. Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. Journal of Clinical Oncology. 2014; 32(32): 3607–3612.
  69. Farge D, Trujillo-Santos J, Debourdeau P, et al. RIETE Investigators.. Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Medicine (Baltimore). 2015; 94(32): e1235.
  70. Schulman S, Zondag M, Linkins L, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015; 13(6): 1010–1018.
  71. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017; 157: 90–96.
  72. Brighton TA, Eikelboom JW, Mann K, et al. ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012; 367(21): 1979–1987.
  73. Becattini C, Agnelli G, Schenone A, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012; 366(21): 1959–1967.
  74. Gervaso L, Dave H, Khorana A. Venous and Arterial Thromboembolism in Patients With Cancer. JACC: CardioOncology. 2021.
  75. Bikdeli B, Chatterjee S, Kirtane AJ, et al. Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Semin Thromb Hemost. 2020; 46(8): 908–918.
  76. Mannello F, Medda V, Ligi D, et al. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013; 11(3): 354–365.
  77. Mannello F, Raffetto JD. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res. 2011; 3(2): 149–158.
  78. Mattana P, Mannello F, Ferrari P, et al. Vascular pathologies and inflamma-tion: The anti-inflammatory properties of sulodexide. Italian Journal of Vascular and Endovascular Surgery. 2012; 19: 1–7.
  79. Połubińska A, Staniszewski R, Baum E, et al. Sulodexide modifies intravascular homeostasis what affects function of the endothelium. Adv Med Sci. 2013; 58(2): 304–310.
  80. Sosińska P, Baum E, Maćkowiak B, et al. Sulodexide Reduces the Proinflammatory Effect of Serum from Patients with Peripheral Artery Disease in Human Arterial Endothelial Cells. Cell Physiol Biochem. 2016; 40(5): 1005–1012.
  81. Suminska-Jasinska K, Polubinska A, Ciszewicz M, et al. Sulodexide reduces senescence-related changes in human endothelial cells. Med Sci Monit. 2011; 17(4): CR222–CR226.
  82. Bręborowicz A. Sulodexide — mixture of glycosaminoglycans with the pro-tective effect towards the vascular endothelium. Acta Angiologica. 2014; 20(3): 112–8.
  83. Konstantinides SV, Meyer G, Becattini C, et al. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019; 54(3).
  84. Tomkowski W, Kuca P, Urbanek T, et al. Żylna choroba zakrzepowo-zatorowa — wytyczne profilaktyki, diagnostyki i terapii. Konsensus Polski 2017. Acta Angiologica. 2017; 23(2): 73–113.
  85. Andreozzi GM, Bignamini AA, Davi G. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2016; 4(4): 536.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl